First Horizon Advisors, Inc. Alnylam Pharmaceuticals, Inc. Transaction History
First Horizon Advisors, Inc.
- $3.81 Billion
- Q2 2025
A detailed history of First Horizon Advisors, Inc. transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 187 shares of ALNY stock, worth $82,079. This represents 0.0% of its overall portfolio holdings.
Number of Shares
187
Previous 124
50.81%
Holding current value
$82,079
Previous $33,000
81.82%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding ALNY
# of Institutions
746Shares Held
110MCall Options Held
966KPut Options Held
841K-
Capital World Investors Los Angeles, CA16.7MShares$7.35 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$5.73 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.19 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$3.14 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.94 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $54B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...